[Special Stock] Helixmith Gains for 3 Consecutive Days as Enzygnosis Achieves Primary Endpoint in China Phase 3 Trial

Helixmith has been on a three-day winning streak. This is interpreted as being influenced by the news that 엔젠시스 (VM202, Chinese name NL003) achieved the primary endpoint in its Phase 3 clinical trial in China.

As of 9:28 AM on the 6th, Helixmith is trading at 6,890 KRW, up 20.24% from the previous day. Helixmith had hit the daily limit up on the 2nd and the previous day.

Helixmith announced on the 2nd that its Chinese partner, Northland Biotech, achieved the primary endpoint in a Phase 3 clinical trial using 엔젠시스 for the complete healing of ulcers in patients with critical limb ischemia (CLI).

According to the results announced by Northland, the primary endpoint of ulcer healing rate was significantly superior compared to the placebo group (p<0.0001), safety was favorable, and no serious adverse reactions were observed.

Northland initiated two independent Phase 3 clinical trials in July 2019 across 24 clinical trial centers throughout China: one Phase 3 trial (with 300 patients) targeting pain reduction during the resting phase as the primary endpoint, and another Phase 3 trial (with 240 patients) targeting complete ulcer healing as the primary endpoint. The current results pertain to the Phase 3 trial aimed at ulcer healing. Results for the other Phase 3 trial targeting pain reduction are expected to be announced in the third quarter of this year.

Previously, in 2004, Helixmith and Northland Biotech signed a co-development agreement. When Northland commercializes 엔젠시스 in China, Helixmith will receive royalties for a certain period.